Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2180)	6/25/2009 12:27:57 PM
From: Jibacoa	Respond to of 3722

CYTR was up 25.16% at its intraday H and is still up 14.62% at present. It announced that an experimental animal trial produced statistically significant evidence that its arimoclomol provided protection from the detrimental cognitive and sensorimotor effects of hypoxia. Data from this trial will be presented in a poster, on July 9 at the 37th Annual International Society on Oxygen Transport to Tissue (ISOTT) Conference, being held in Cleveland, Ohio. <g> Volume of > 1,851,900 is already 2x its ADV The stock has been on a near term UT since early May bigcharts.marketwatch.com If the stock can close above the resistance at the $1 level, it seems it could have further % gains. <g> bigcharts.marketwatch.com CYTR has no significant LTD, but has been burning its cash at a pretty good clip. Bernard